Wound Heal
Conditions
Keywords
MOHS surgery, amnion membrane powder, scalp wound healing
Brief summary
The purpose of this research study is to test the safety of the amnion membrane powder to see if it improves wound healing in patients undergoing Mohs surgery on the scalp.
Detailed description
The primary objective of this prospective, non-randomized, controlled study is to assess the safety of the human amnion membrane powder for enhanced wound healing properties in patients undergoing Mohs surgery resulting in full thickness wounds. The secondary objective is to evaluate the efficacy of the product relative to the standard of care treatment in a control cohort of subjects. The treatment site will be the wound created by the Mohs surgery in the treatment group. The proposed sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
Interventions
amnion membrane power dose of 0.26 mg/mm3 applied during MOHS scalp surgery
DRUGStandard of Care
aquaphor ointment applied during MOHS scalp surgery
Sponsors
Wake Forest University Health Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject requires Mohs surgery on the scalp, with the resulting wound extending to the subgalea (all subcutaneous fat removed) and a surface area of at least 4cm2. * The subject is willing to complete all follow-up evaluations required by the study protocol. * The subject is to abstain from any other covering or treatment of the wound(s) for the duration of the study unless otherwise directed by the study surgeon or their surrogate * The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. * The subject and/or guardian is/are able to read and understand instructions and give informed, voluntary, written consent. * The subject is able and willing to follow the protocol requirements.
Exclusion criteria
* The subject's wound site is smaller than 4cm2. * The subject's wound site does not extend to the subgalea. * The subject has invasive melanoma or high-risk squamous cell carcinoma (defined by poor differentiation, presence of perineural invasion) in which the standard of care is to be referred for adjuvant radiation oncology * The subject has a microbiologically proven pre-existing local or systemic bacterial infection. * The subject has been receiving a systemic antibiotic for more than 48 hours prior to grafting. * Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and/or other interventional procedure that would preclude the indicated procedure. * Hepatic disease or altered liver function as defined by ALT or AST value \> 3 times the upper limit of normal and/or T. Bilirubin \>1.5 mg/dL at screening. * Renal disease or altered renal function as defined by serum creatinine \> 2 mg/dL at screening, or ESRD. * Hemoglobin \<10.0 or \>19.0 g/dL * Untreated coagulopathy or platelet disorder, or INR \> 1.6, PTT \> 38 sec; PLT \< 50,000 at screening. * The subject is known to have a pre-existing, chronic condition that, in the opinion of the Investigator, may interfere with complete re-epithelialization including but not limited to untreated malignancy, uncontrolled diabetes (HbA1c \>10), autoimmune disease or other immunocompromised diseases, hematological diseases, peripheral artery diseases, and /or malnourishment with an albumin \< 2.5. * The subject currently uses illicit substances or has drug or alcohol dependency. * The subject is unable to follow the protocol. * The subject is taking medication known to have an effect on wound healing or skin pigmentation within 30 days prior to surgery (e.g. corticosteroids, retinoids etc.) * The subject has a known hypersensitivity to Compound Sodium Lactate for Irrigation (Hartmann's) solution. * The subject is pregnant or lactating or intends to become pregnant during the study. * The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Infection | Through week 16 | Number of participants that developed a wound infection |
| Number of Participants with Allergic Reaction | Through week 16 | Number of participants with an allergic reaction to the intervention |
| Number of Treatment-Related Adverse Events | Through week 16 | Number of treatment-related adverse events |
| Number of Unscheduled Visits for Wound Bleeding | Through week 16 | Number of participants that had an unscheduled visit for wound bleeding |
| Pain Score | Baseline | Participants asked rate their pain on a scale of 1-10 with 10 being worst pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time Until Wound Closure | Through week 16 | Number of days until wound was completely closed |
| Time Until of Wound Closure | Through week 16 | Number of days until wound was fully sealed |
| Percentage of Re-epithelialization | Week 1, week 4, week 8, week 12, week 16 | Percentage of the wound with re-epithelialization |
Countries
United States
Contacts
CONTACTMary-Clare Day
PRINCIPAL_INVESTIGATORChristine Ahn, MD
Atrium Health Wake Forest Baptist
Outcome results
None listed